Industry focus: Healthcare and life sciences

Osborne Clarke

The broad and ‘extremely competent’ offering at Osborne Clarke often assists clients which are active within the medtech and pharma industries, particularly in relation to rare diseases. Thomas Devred leads the team, and is well equipped to advise on licensing, market access, and supply chain issues, in addition to handling data privacy issues involving patient data. Regulatory expert Léa Masson-Boukobza often acts for medical device and pharma clients in matters involving anti-gift rules, advertising, and clinical trials.

Legal 500 redaktioneller Kommentar

Profil: osborneclarke.com

Soziale Medien

Referenzen

Unabhängig vom Legal 500-Forschungsteam zusammengestellt.

‘The team is extremely competent and fully invested in answering the questions asked. I warmly recommend this team and in particular Thomas Devred who is a very great professional.’
‘Thomas Devred has extensive experience in this field. His industry experience is a major asset in answering the questions and expectations of his clients.’
‘In-depth analysis, quality of exchanges, responsiveness and availability.’
‘Léa Masson-Boukobza - in-depth analyses and quality advice, responsiveness. Thomas Devred - responsiveness, taking into account constraints and internal policies in the analysis of the cases presented to him.’
‘Diverse expertise.’
‘Very responsive and available, always ready to support the customer.’

Kernmandanten

Act for Health - Pro Case Management
Amryt Pharmaceuticals
Corin
FédéPSAD
Grifols
Horizon Therapeutics
Karl Storz
Santhera Pharmaceuticals
Revolution Medicines
Unicancer

Highlight-Mandate

Advised Grifols on the acquisition of Biotest and integration of compassionate use programmes for pharma products.
Advised Karl Storz on an R&D cooperation to train artificial intelligence with patients' data and upgrade medical devices.
Advised Santhera Pharma on digital communication for the launch of a rare disease pharma product.

The Legal 500

FAQs

Newsletter

Kontakt